Matching articles for "Enhertu"
In Brief: An Expanded Indication for Enhertu
Fam-trastuzumab deruxtecan ( Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in combination with pertuzumab (Perjeta) for first-line treatment of HER2-positive unresectable or…
Med Lett Drugs Ther. 2026 May 25; 68(1755):87 doi:10.58347/tml.2026.1755d
Fam-trastuzumab deruxtecan ( Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in combination with pertuzumab (Perjeta) for first-line treatment of HER2-positive unresectable or metastatic breast cancer. The drug was approved earlier for use as monotherapy in adults with previously treated HER2-positive unresectable or metastatic breast cancer.
In Brief: Fam-trastuzumab deruxtecan (Enhertu) for Breast Cancer (online only)
Fam-trastuzumab deruxtecan-nxki ( Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of…
Med Lett Drugs Ther. 2023 Apr 3; 65(1673):e60-1 doi:10.58347/tml.2023.1673f
Fam-trastuzumab deruxtecan-nxki ( Enhertu – Daiichi Sankyo/AstraZeneca), which received accelerated approval by the FDA in 2019 for treatment of HER2-positive breast cancer based on its rate and duration of response,1 has been granted regular approval for treatment of adults with unresectable or metastatic HER2-positive breast cancer who received a prior anti-HER2-based regimen in the metastatic setting or in the neoadjuvant or adjuvant setting and developed recurrence during or within 6 months of completing treatment.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (…
Med Lett Drugs Ther. 2020 Nov 16; 62(1611):182-4
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki ( Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib ( Tukysa – Seagen), an oral tyrosine kinase inhibitor.
